Editorial Commentary
The dry retina paradox: interpreting MERLIN in clinical practice
AME Clinical Trials Review
2026;
4:
31
.
(25 June 2026)
Editorial Commentary
Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2
AME Clinical Trials Review
2026;
4:
30
.
(25 June 2026)
Editorial Commentary
Androgen deprivation therapy and definitive radiotherapy for intact prostate cancer in the modern era: personalized medicine on the horizon
AME Clinical Trials Review
2026;
4:
29
.
(25 June 2026)
Editorial Commentary
We will not have to wait—building regulatory confidence in early endpoints for high-risk breast cancer
AME Clinical Trials Review
2026;
4:
28
.
(25 June 2026)
Editorial Commentary
Precision in practice: a new standard in early-relapsing HR+ breast cancer
AME Clinical Trials Review
2026;
4:
27
.
(25 June 2026)
Editorial Commentary
Less is more: lessons from adding antiangiogenesis to 1L chemo-immunotherapy in non-small cell lung cancer (LEAP-006)
AME Clinical Trials Review
2026;
4:
26
.
(25 June 2026)
Editorial Commentary
EPIK-O and beyond: PI3Kα inhibition plus PARP blockade in platinum-resistant BRCA-wildtype ovarian cancer
AME Clinical Trials Review
2026;
4:
25
.
(25 June 2026)
Editorial Commentary
Neoadjuvant osimertinib: a new standard in resectable EGFR-mutated non-small cell lung cancer?
AME Clinical Trials Review
2026;
4:
24
.
(25 June 2026)
Editorial Commentary
Where are we LEAPing with anti-angiogenics and immunotherapy combinations?—reflections from the LEAP-008 study
AME Clinical Trials Review
2026;
4:
23
.
(25 June 2026)
Editorial Commentary
Extensive-stage small cell lung cancer: progress, slowly but surely
AME Clinical Trials Review
2026;
4:
22
.
(25 June 2026)
Letter to the Editor
Reply to: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial
AME Clinical Trials Review
2026;
4:
21
.
(25 April 2026)
Letter to the Editor
Response to “Steroid-Limited Isatuximab-Based Quadruplet Therapy in Elderly, Transplant-Ineligible Multiple Myeloma: A REST Trial Commentary”
AME Clinical Trials Review
2026;
4:
20
.
(25 April 2026)
Editorial Commentary
Revisiting CDK4/6 inhibition and SERDs: EMBER-3 and the path forward
AME Clinical Trials Review
2026;
4:
19
.
(25 April 2026)
Editorial Commentary
Reframing the immunotherapy landscape in borderline resectable pancreatic ductal adenocarcinoma: progress or plateau?
AME Clinical Trials Review
2026;
4:
18
.
(25 April 2026)
Editorial Commentary
Current and around-the-corner therapies in platinum-resistant ovarian cancer: an insight into the ROSELLA study
AME Clinical Trials Review
2026;
4:
17
.
(25 April 2026)
Editorial Commentary
Cachexia, cytokines, and caution: lessons from tocilizumab in advanced pancreatic ductal adenocarcinoma
AME Clinical Trials Review
2026;
4:
16
.
(25 April 2026)
Editorial Commentary
Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial
AME Clinical Trials Review
2026;
4:
15
.
(25 April 2026)
Editorial Commentary
Not so fast—should neoadjuvant chemotherapy be routine in resectable pancreatic cancers?
AME Clinical Trials Review
2026;
4:
14
.
(25 April 2026)
Editorial Commentary
Steroid-limited isatuximab-based quadruplet therapy in elderly, transplant-ineligible multiple myeloma: a REST trial commentary
AME Clinical Trials Review
2026;
4:
13
.
(25 April 2026)
Review Article
A literature review and reflection on clinical trials: current challenges, future directions, and potential strategies to overcome practical barriers
AME Clinical Trials Review
2026;
4:
12
.
(25 April 2026)
Letter to the Editor
Reply to: Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer
AME Clinical Trials Review
2026;
4:
11
.
(25 February 2026)
Editorial Commentary
Chimeric antigen receptor T cell therapy in prostate cancer: racing to prime time
AME Clinical Trials Review
2026;
4:
10
.
(25 February 2026)
Editorial Commentary
Long-term clopidogrel for secondary prevention—towards resolution of complex problem?
AME Clinical Trials Review
2026;
4:
9
.
(25 February 2026)
Editorial Commentary
Encorafenib, cetuximab and chemotherapy: a mole against BRAF mutant metastatic colorectal cancer
AME Clinical Trials Review
2026;
4:
8
.
(25 February 2026)
Editorial Commentary
Ibrutinib’s role in early-stage chronic lymphocytic leukemia: delayed progression but no survival advantage
AME Clinical Trials Review
2026;
4:
7
.
(25 February 2026)
Editorial Commentary
Asciminib: a revolution in the tyrosine kinase inhibitors era
AME Clinical Trials Review
2026;
4:
6
.
(25 February 2026)
Editorial Commentary
The role of lisocabtagene maraleucel for relapsed/refractory follicular lymphoma: a commentary
AME Clinical Trials Review
2026;
4:
5
.
(25 February 2026)
Review Article
From the PACIFIC to the ADRIATIC: a literature review of 38 years of failed maintenance trials in small cell lung cancer post-chemoradiation
AME Clinical Trials Review
2026;
4:
4
.
(25 February 2026)
Review Article
Clinical advancements in total neoadjuvant therapy for locally advanced rectal cancer: a narrative review
AME Clinical Trials Review
2026;
4:
3
.
(25 February 2026)
Review Article
The role of minimal residual disease measurement in multiple myeloma
AME Clinical Trials Review
2026;
4:
2
.
(25 February 2026)